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BASIC INVESTIGATIONS
Intradermal Anti-Loxosceles Fab Fragments Attenuate
Dermonecrotic Arachnidism
HERNAN F. GOMEZ, MD, MARK J. MILLER, PHD, JOSEPH W. TRACHY, BS,
RORY M. MARKS, MD, JEFFREY S. WARREN, MD
Abstract. Objective: Bites from the brown recluse
spider and other arachnids from the genus Loxosceles
frequently induce necrotic skin lesions that can be
recalcitrant to treatment and disfiguring. The au-
thors used a rabbit model of dermonecrotic arach-
nidism to address the therapeutic efficacy of intra-
dermal (id) polyclonal anti-Loxosceles Fab fragments
(aLoxd Fab) raised against Loxosceles deserta spider
venom. Methods: Fab fragments were prepared by
papain digestion and affinity chromatography from
the IgG fraction of L. deserta antivenom raised in rab-
bits. Eighteen inbred New Zealand white rabbits
were assigned to six groups of three. The rabbits re-
ceived L. deserta venom (3 mg, id) injections into each
flank. Cohorts of rabbits received single id injections
(at one venom site/rabbit) of 30 mg aLoxd Fab at dif-
ferent times (T = 0, 1, 2, 4, 8, and 12 hours) after
venom injection. In each rabbit the opposite flank was
left untreated. As an additional control, one group of
rabbits (T = 0) received nonspecific Fab (30 mg, id) in
the opposite flank. Dermal lesions were quantified as
a function of time through the use of a series of digital
photographs and imaging software. In addition, my-
eloperoxidase (MPO) activity, a measure of neutrophil
accumulation, was determined in lesion biopsies. Le-
sion areas and MPO activities were analyzed by re-
peated-measures analysis of variance (ANOVA). Re-
sults: Lesion areas and MPO activity were markedly
reduced when aLoxd Fab was administered very
early after venom injections. As the interval between
venom inoculation and antivenom treatment in-
creased, the therapeutic benefit of aLoxd Fab de-
creased. The final time tested that demonstrated
therapeutic efficacy of aLoxd Fab was T = 4 hours.
Lesion attenuation was no longer apparent when
aLoxd Fab was given 8 hours post inoculation. Con-
clusions: Intradermal administration of aLoxd Fab
attenuates Loxosceles-induced dermonecrotic lesion
formation when given up to 4 hours after venom
inoculation in this rabbit model. Key words: Lox-
osceles; spider; venom; Fab fragments; arachnidism.
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MORE THAN 10,000 spider bites were re-ported to the American Association of Poi-
son Control Centers (AAPCC) Toxic Exposure Sur-
veillance System (TESS) in 1996.1 Although bites
from the brown recluse spider are rarely fatal, the
manifestations of these bites are nonetheless sig-
nificant. Nine hundred thirty of the brown recluse
spider bites reported to TESS in 1996 resulted in
minor to major morbidity.1 Loxosceles arachnids
are indigenous American spiders that possess a
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venom capable of causing intense dermal inflam-
mation and disfiguring necrotic ulcers.2,3 In some
cases the bite site may resemble pyoderma gan-
grenosum or other neutrophilic dermatoses.4 Clin-
ical presentation varies from local cutaneous in-
flammation and necrosis to systemic loxoscelism.
The bite, which initially may cause only minor dis-
comfort, begins as an enlarging circular area of
erythema and edema. A centrally located necrotic
ulcer often forms 8–24 hours following enven-
omation.2,3 Among the 13 recognized species of
Loxosceles that are found in the United States, L.
reclusa, commonly called the brown recluse spider,
is the major species responsible for envenomation.
Most Loxosceles envenomations occur in the south
central regions of North America.5
Although characteristic Loxosceles arachnid-in-
duced skin lesions were first described in the med-
ical literature by Caveness in 1872,6 a consistently
effective treatment has yet to be demonstrated.
The literature is replete with circumstantial re-
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Figure 1. Schematic diagram of the investigation pro-
tocol. L. deserta = Loxosceles deserta; id = intradermal;
aLoxd Fab = anti-Loxosceles Fab fragments; p = post;
MPO = myeloperoxidase; IL-8 = interleukin-8.
ports and uncontrolled studies of recluse lesion
therapies. Several studies attest to the potential
efficacy of dapsone7 or hyperbaric oxygen therapy,8
but these therapies have not been studied in hu-
mans in a controlled fashion, and recent blinded
animal studies have failed to reveal differences be-
tween treatment groups and their respective con-
trols.9,10 Literature regarding the use of polyclonal
anti-Loxosceles antibody (Ab) is somewhat lim-
ited. Rees et al. administered rabbit derived anti-
Loxosceles polyclonal IgG Ab intradermally (id) to
rabbits 6–48 hours after envenomation with L.
reclusa venom.11 These authors noted decreases in
Ab-treated lesion size in rabbits treated up to 24
hours after envenomation, though the difference at
24 hours was minute, and a statistical analysis
was not conducted.11 Rees et al. subsequently com-
pared lesion sizes in human spider bite victims
treated with anti-Loxosceles polyclonal IgG Ab.12
In this investigation, lesion sizes were compared
among patients treated with id Ab, those treated
with dapsone and Ab, and those treated with dap-
sone alone.12 No significant differences among
groups of patients were observed.12 Bravo et al.
tested intradermal equine polyclonal anti-L. laeta
Ab in rabbits inoculated with L. laeta venom.13 In-
cubation of venom with Ab for one hour before in-
oculation prevented lesion development in rabbits,
and lesions were attenuated when Ab treatment
was delayed for one hour after venom inocula-
tion.13 Recently, Cole et al. reported that anti-Lox-
osceles polyclonal IgG Ab attenuates lesional ery-
thema and necrosis in a rabbit model of eyelid
envenomation.14
Fab fragments have been developed to treat a
variety of conditions, including digoxin15 colchi-
cine,16 tricyclic antidepressant,17 and phencycli-
dine overdoses18 as well as Crotalidae snake-
bites.19,20 In order to improve safety and efficacy in
humans, intact IgG Ab is cleaved with papain,
yielding two antigen-binding Fabs, each with a mo-
lecular weight of approximately 50,000 daltons
and one Fc fragment.21 Since the Fc fragment does
not bind antigen, and it increases the potential for
hypersensitivity reactions, it is eliminated. Fabs
have several advantages over intact Ab in the
treatment of drug or venom toxicity. These include
a larger volume of distribution, more rapid onset
of action, smaller risk of adverse immunologic ef-
fects, and more rapid elimination.21–23 We therefore
investigated the hypothesis that polyclonal anti-
Loxosceles Fab fragments will inhibit dermone-
crotic inflammation associated with Loxosceles en-
venomation.
METHODS
Study Design. This was a prospective, random-
ized, controlled laboratory investigation examining
the efficacy of Fab fragment Loxosceles antivenom
in attenuating venom-induced dermal inflamma-
tion in a rabbit model. The study was approved by
the University of Michigan Committee on the Use
and Care of Animals. All experiments were in ac-
cord with the standards in The Guide for the Care
and Use of Laboratory Animals, and were super-
vised by veterinarians from the Unit for Labora-
tory and Animal Care of the University of Michi-
gan Medical School.
Study Participants. Eighteen inbred New Zea-
land white rabbits were assigned to six groups of
n = 3 (Fig. 1). The rabbits received L. deserta
venom (3 mg id) into each flank. This venom dose
was chosen since it resulted in reproducible (and
easily measured) lesion areas in the 30–50-cm2
range in pilot animals. The actual amount of
venom deposited into prey by Loxosceles sp. spi-
ders is unknown. The six cohorts of n = 3 rabbits
ACADEMIC EMERGENCY MEDICINE • December 1999, Volume 6, Number 12 1197
received single id injections (at one venom site/rab-
bit) of 30 mg anti-Loxosceles Fab fragments (aLoxd
Fab) antivenom at different times (T = 0–12 hr)
after venom inoculation. The opposite flank was
left untreated as a control. An additional control of
30 mg id non-venom-specific Fab treatment imme-
diately following venom injection (T = 0) was also
included (n = 3). The dosage of 30 mg of aLoxd Fab
was selected after pilot studies demonstrated con-
sistent marked attenuation of venom-induced der-
mal inflammation at this selected dose.
Study Protocol. For all groups, digital photo-
graphs of evolving lesions were taken during the
48 hours following Fab administration. The images
were imported into a computer, and evolving lesion
areas were traced and measured using NIH im-
aging software. Myeloperoxidase (MPO) activity (a
sensitive measure of neutrophil accumulation) was
determined at 48 hours in multiple lesion biopsies
obtained 0–8 cm from the site of envenomation. In
addition, interleukin-8 (IL-8) tissue content was
determined at the earliest time point tested
(T = 0).
Antibody Production. Polyclonal IgG antibody to
L. deserta venom (SpiderPharms, Feasterville, PA)
was raised in New Zealand white rabbits. The rab-
bits received intramuscular L. deserta venom in-
jections every three weeks for a period of five
months. The IgG was purified using a modification
of the method described by Goding24 and Coulter
et al.25 Immune rabbit IgG was purified from
crude serum via affinity chromatography by flow-
ing crude serum diluted 1:3 with ImmunoPure
binding buffer (Pierce, Rockford, IL) through an
AffinityPak protein A-sepharose column (Pierce).
The Fc portion of intact Ab binds to protein A,24
thus allowing other serum proteins to flow through
the column to be discarded. The bound IgG is
eluted with ImmunoPure elution buffer, pH 3
(Pierce), and dialyzed against phosphate-buffered
saline (PBS), pH 7.4. We have previously demon-
strated that polyclonal IgG antibody raised against
L. deserta venom effectively blocks dermal lesion
development from both L. reclusa and L. deserta
spider venoms.26
Fab Fragment Preparation and Purification.
The procedure used to prepare Fab fragments
was modified from that described by Coulter and
Harris.27 Purified IgG Ab was dialyzed against a
20-mM phosphate/10-mM ethylenediamine tetra-
acetic acid (EDTA) buffer, pH 7.0, and concen-
trated to a 20-mg/mL solution. Aliquots of purified
IgG Ab were added to a digestion buffer consisting
of cysteine HCl dissolved in a phosphate buffer (pH
10). Immobilized papain slurry was then added to
the solution. The resultant suspension was incu-
bated for five hours in an air shaker at 377C to
maintain constant mixing of papain and Ab. Pa-
pain was then removed using a proprietary filter
separator tube (Pierce). The Fc and Fab fragments
contained in the crude digest were separated using
a prepacked column of immobilized protein A (Af-
finity-Pak). The Fab fragments were dialyzed
against PBS (pH 7.4) and concentrated to 30 mg/
mL. IgG and Fab concentrations were determined
by spectrophotometry at 279 nm (LKB Ultrospec II
Model 450, Biochrom, Cambridge, England). The
aLoxd Fab molecular weight was determined to be
approximately 40,000 daltons by sodium dodecyl-
sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). Protein molecular weight standards were
obtained from Amersham (Arlington Heights, IL,
RPN 756).
MPO Activity Determination. Myeloperoxidase
activity, a sensitive measure of neutrophil accu-
mulation, was measured in dermal biopsies. At the
time of sacrifice, 4-mm punch biopsies were taken
from predetermined distances (0–8 cm) from the
inoculation site and instantly frozen with liquid ni-
trogen. Using a polytron tissue homogenizer (Tis-
sue Tearor, Biospec, Bartlesville, OK), the skin bi-
opsies were homogenized on ice in 500-mL PBS (pH
7.4) containing 0.1% Tween 20. Samples were son-
icated on ice and insoluble material was removed
by centrifugation at 3,000 rpm for 10 minutes. Five
mL of tissue extract (PBS pH 7.4 and 0.1% Tween
20) was incubated with 100 mL of 2,29-azino-di-(3-
ethylbenzthiozoline sulfonate) diammonium salt
solution (ABTS substrate, Boehringer Mannheim,
Indianapolis, IN) in triplicate and the maximum
velocity of the substrate/MPO chromogenic reac-
tion (Vmax) was measured by monitoring the 96-
well low-protein binding flat-bottom plates (Corn-
ing Glass Works, Corning, NY) at 405 nm over
a 2-minute period (BioTek ELx808 microplate
reader, Bio-Tek Instruments, Inc., Winooski, VT).
Kinetic calculations were performed using KC3
software (Bio-Tek). The MPO activity in samples
was determined using a standard curve of purified
MPO (Calbiochem, San Diego, CA). The MPO val-
ues are reported as units of activity/biopsy.
IL-8 Tissue Content Determination. The en-
zyme immunoassay (EIA) method used for this in-
vestigation is a modification of the enzyme-linked
immunosorbent assay (ELISA) procedure to detect
soluble antigens.28 Standard 96-well, flat-bottom
ELISA plates (Corning Glass Works) were coated
with murine monoclonal IgG1 antibodies (courtesy
Genentech, San Francisco, CA) specifically di-
rected against rabbit IL-8. After overnight binding
of the capture antibody (4 mg/mL in PBS pH 7.4),
ELISA plates were incubated with blocking buffer
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Figure 2. Fab antivenom and control lesion areas over time. Fab antivenom markedly suppressed the venom effect
when administered early, with decreasing efficacy over time. Control and lesion area differences were not significant
by T = 8 hr. aLoxd Fab = anti-Loxosceles Fab fragments.
[PBS pH 7.4, 1% bovine serum albumin (BSA),
0.05% Tween 20] for two hours, and washed twice
(0.05% Tween 20 in PBS). Conditioned medium
and standards were added in triplicate for a two-
hour incubation period. Plates were washed twice
with buffer followed by the addition of biotinylated
chicken polyclonal IgY detection anti-rabbit IL-8
antibody 2 mg/mL. The polyclonal IgY detection an-
tibody to rabbit IL-8 was generated by immunizing
chickens with recombinant rabbit IL-8, and isolat-
ing immunoglobulin from egg yolks. Antigen spec-
ificity was confirmed by showing that the antibody
bound recombinant IL-8 as well as native rabbit
macrophage-derived IL-8, as assessed by radioim-
munoprecipitation, Western blotting, and immu-
nohistochemistry, and neutralized IL-8-induced
neutrophil chemotaxis and calcium flux in vitro
(Marks RM, Chen Y, Suarez TM, unpublished data,
1995). After the plates were washed four times
with buffer, streptavidin horseradish peroxidase
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1:4,000 dilution (Neutralite, 7200-05, Southern
Biotechnology Associates, Inc., Birmingham, AL)
was added for 30 minutes. The plates were then
washed six times with EIA wash buffer, and finally
exposed to 2,29-azino-di-(3-ethylbenzthiozoline sul-
fonate) diammonium salt solution (ABTS sub-
strate, Boehringer Mannheim, #1 112 422) for 35–
40 minutes. Absorbance was read at 405 nm on a
model ELX808, Bio-Tek microplate reader. Inter-
leukin-8 concentrations were calculated by four-
parameter curve fitting or linear regression anal-
ysis of chemokine standard curves using KC3
software (Bio-Tek).
Data Analysis. Lesion areas, MPO activities,
and IL-8 concentrations were analyzed and com-
pared using repeated-measures analysis of vari-
ance (ANOVA).
RESULTS
Lesion Area Determination. When aLoxd Fab
antivenom was administered id immediately (T =
0 hr) after envenomation, lesion development was
essentially blocked (Fig. 2). At 48 hours the control
lesion had reached a mean (6SD) area of 41.9 6
11.3 cm2, compared with a small transient ery-
thema noted at the aLoxd Fab antivenom site,
which had resolved by the end of the 48-hour study
period (ANOVA p = 0.005, Fig. 2). The control re-
sults were similar at T = 0 hr using the nonspecific
Fab control (results not shown). The aLoxd Fab
antivenom continued to suppress the lesion areas
when administered T = 1 hr up to T = 4 hr after
L. deserta envenomation, although the longer
aLoxd Fab antivenom treatment was delayed, the
smaller the difference in treatment and control le-
sion areas (Fig. 2). At T = 4 hr the treatment lesion
was attenuated with a mean 6 SD area of 20.4 6
5.9 cm2 compared with the control mean (6SD)
area of 31.2 6 12.5 cm2 (ANOVA p = 0.02). Mean
area differences were not significant after aLoxd
Fab antivenom treatment delays of T = 8 hr and T
= 12 hr (Fig. 2).
MPO Activity Determination. When aLoxd Fab
was administered immediately after envenoma-
tion, MPO activity was markedly attenuated. At
the site of envenomation at T = 0 hr, the control
lesion had a mean (6SD) MPO activity level of 3.2
6 1.8 u/mL compared with the aLoxd Fab cohort
mean (6SD) MPO activity level of 0.13 6 0.09
u/mL (ANOVA p = 0.004, Fig. 3). As the delay in
aLoxd Fab antivenom treatment post Loxosceles
envenomation increased, the difference in MPO ac-
tivity diminished (Fig. 3). When aLoxd Fab anti-
venom was administered at T = 4 hr post enven-
omation (after dermal erythema and induration
were well under way), MPO activity was still
markedly diminished throughout the Fab treat-
ment lesion (ANOVA p = 0.01, Fig. 3). If treatment
was delayed eight or more hours after envenoma-
tion, the lower mean MPO activity levels in the
aLoxd Fab antivenom treatment side were no
longer different (Fig. 3).
Interleukin-8 Tissue Concentration. Loxosceles
venom has been found to stimulate the secretion
of IL-8 by endothelial cells.29 We determined the
IL-8 dermal tissue concentrations in the T = 0 hr
aLoxd Fab antivenom cohort at the end of the 48-
hour study period. Lesional IL-8 tissue concentra-
tions were lower in the aLoxd Fab antivenom
treatment lesions sampled, with mean (6SD) IL-8
levels of 0.03 6 0.02 ng/mL at the venom inocula-
tion sites compared with a mean (6SD) of 0.21 6
0.03 ng/mL noted on the control NS Fab enven-
omation sites (Fig. 4).
DISCUSSION
In this investigation, intradermally administered
anti-Loxosceles Fab fragments were shown to in-
hibit the formation of venom-induced dermal in-
flammation in the rabbit model. The lesion areas
and MPO activity levels were markedly attenuated
when Fabs were administered early after Loxos-
celes envenomation. There was decreasing efficacy
of the lesion attenuating effect of Fab treatment as
treatment time was delayed (and dermal inflam-
mation was well under way) after envenomation.
Decreased therapeutic efficacy with delay in poly-
clonal IgG antivenom treatment has previously
been observed in the rabbit model using intact an-
tibody.11,13,14 At least two hypotheses may explain
the time-dependent decrease in therapeutic effect.
First, if venom has spread in dermal tissue over
time, an id injection of antivenom at the original
envenomation site may not have physical access
for complete neutralization of venom. Evidence for
this hypothesis exists in an investigation recently
reported by us.30 Rabbits envenomated with a large
dose (20 mg) of L. deserta venom developed a ‘‘dou-
ble’’ necrotic lesion with small areas of necrosis ap-
pearing to ‘‘drip’’ down the side of the animal.30 Us-
ing a modified tissue EIA assay, Loxosceles venom
was detected throughout a 15-cm necrotic inflam-
matory dermal lesion after 24 hours.30 Systemi-
cally administered aLoxd Fab antivenom might be
one way to neutralize venom that has migrated
from the envenomation site. Another contributing
factor for the observed decrease in efficacy with an-
tivenom treatment delay is that Loxosceles anti-
venom neutralization may be less efficacious in
modifying inflammatory events once they are well
under way. In this investigation, the control and
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Figure 3. Fab antivenom and control myeloperoxidase (MPO) activity levels over time. Fab antivenom markedly
suppressed the venom effect when administered early, with decreasing efficacy over time. Control and lesion MPO
differences were not significant by T = 8 hr. 0 cm = site of Loxosceles venom inoculation. aLoxd Fab = anti-
Loxosceles Fab fragments.
treatment lesions in the T = 8 hr and T = 12 hr
cohorts had already reached a dermal inflamma-
tion area of 15 cm2 or more prior to initiation of
treatment.
Loxosceles venom has been found to stimulate
the secretion of IL-8 by endothelial cells.29 We
found that aLoxd Fab administered immediately
after venom inoculation inhibits tissue levels of IL-
8. Biological features of IL-8, compared with other
chemotactic factors, include physiologic effects on
neutrophils both in vitro and in vivo.31 In-vitro ac-
tivities of IL-8 include a shape change and acti-
vation of the motile system of the neutrophil.31
This occurs very rapidly; within 15 seconds of IL-
8 addition to suspensions of neutrophils, actin mi-
crofilaments are redistributed to the subcortical re-
gion of the neutrophil.31 In vivo, intradermal
injections of human IL-8 in rabbits induce plasma
exudation and neutrophil recruitment.32 Interleu-
kin-8 has been shown to be an important mediator
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Figure 4. Tissue interleukin-8 (IL-8) concentrations 48
hours following treatment. Fab antivenom suppressed
dermal IL-8 concentrations when administered immedi-
ately (T = 0) after envenomation. aLoxd Fab = anti-Lox-
osceles Fab fragments.
of other forms of tissue injury such as acid aspi-
ration-induced lung injury and endotoxin-induced
pleurisy.33,34 Thus, the inhibition of IL-8 levels in
dermal tissue may play a role in the reduced
inflammation observed in envenomed animals
treated with the Fab antivenom.
The therapeutic use of Fab fragments in the
treatment of envenomations is a current focus of
toxicologic research. Since the Fc does not bind an-
tigen, and it increases the potential for hypersen-
sitivity reactions, it was eliminated. Fabs have
several advantages over intact Ab in the treatment
of drug or venom toxicity. These include a larger
volume of distribution, more rapid onset of action,
smaller risk of adverse immunologic effects, and
more rapid elimination.21–23 Fabs have been devel-
oped as a safer alternative to the currently avail-
able equine-derived polyvalent crotalid antivenin.
In a recent multicenter trial, Dart et al. reported
that mixed monospecific crotalid antivenin ovine
Fab was associated with the halt of progressive
crotalid venom poisoning without adverse allergic
reactions.19 Clark et al. reported that Fabs were
effective in reversing neurotoxicity associated with
crotalid bites.20 Internationally, Fabs are currently
being investigated as antidotal therapy for the
West African carpet viper (Echis ocellatus),35
Northern Europe common adder (Vipera berus),36
and a Mexican scorpion species (Centruroides nox-
ius Hoffmann).37
LIMITATIONS AND FUTURE QUESTIONS
There are several limitations that should be noted
in this investigation. One limitation pertains to its
unblinded design in lesion area determination,
which does not permit control for investigator bias.
The MPO activity and tissue IL-8 determinations,
however, were performed by a technician blinded
to the source of each sample. Nonspecific Fab frag-
ments were used as a control for the first cohort (T
= 0) but were not applied in remaining cohorts.
This study followed only the lesion area and MPO
activity levels up to 48 hours after initiation of
treatment. Thus, significant attenuating effect by
aLoxd Fab antivenom after the 48-hour investi-
gation period may have been missed, particularly
in cohorts that did not receive treatment many
hours after venom inoculation. In addition, the use
of the same animals for both treatment and control
lesions may have affected the outcome of the study.
Any therapeutic aLoxd Fab injected into an inoc-
ulation site could be absorbed into systemic circu-
lation, and attenuate the size of the control lesion
on the opposite flank.
Several questions are raised by this investiga-
tion. For example, we found that id aLoxd Fab was
efficacious when administered four hours post in-
oculation, but no longer efficacious if administered
at eight hours. Thus, would larger cohorts and op-
timized study conditions demonstrate efficacy for
longer periods of time post inoculation? Optimized
study conditions might include separate control
and study animals, as well as larger cohorts. Also,
if venom does in fact migrate from the initial en-
venomation site, would parenterally administered
aLoxd Fab antivenom provide better access to the
venom and thus enhance neutralization? Is it pos-
sible to identify individuals who may have sus-
tained spider envenomation prior to the develop-
ment of fully expressed dermal necrosis 24–48
hours later? While further research may extend
the efficacy of aLoxd Fab antivenom to an increas-
ing period of time after envenomation, it is none-
theless likely that the antivenom would have little
impact once the dermonecrotic lesion has been
fully established. Finally, could aLoxd Fab anti-
venom be a useful therapeutic option in those in-
dividuals with the systemic form of Loxoscelism?
CONCLUSIONS
In this investigation using the New Zealand rabbit
model, id anti-Loxosceles Fab fragments inhibited
the dermal inflammation and necrosis associated
with Loxosceles envenomation up to four hours
post venom inoculation.
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